News2020-11-03
MVC and NIHE Partner to Develop COVID-19 Vaccine in Vietnam
MVC (TPEx: 6547.TWO) and NIHE, a public institute under the Ministry of Health in Vietnam, today entered a partnership in MVC-COV1901 vaccine development. MVC will conduct clinical trials of MVC-COV1901 vaccine in Vietnam, whereas NIHE provides medical expertise to support the clinical studies and BLA registration via EUA (Emergency Usage Authorization) route in accordance to Vietnam regulations. Both parties will contribute best efforts to seek public and private resources to facilitate MVC-COV1901 vaccine development with the aim to supply COVID-19 vaccine in Vietnam by 2021.
 
NIHE, National Institute of Hygiene and Epidemiology, is a public institution under the Ministry of Health of Vietnam. NIHE oversees the prevention and control of epidemic diseases, and is experienced in conducting scientific research and clinical trials in epidemiology. As one of the national designated institutions to conduct laboratory testing of COVID-19 infections, NIHE has inclusive and updated information of COVID-19 infections in Vietnam, making NIHE one of MVC’s important partners to speed up COVID19 vaccine development. Since Vietnam has over 95 million population and as one of important ASEAN member states, MVC’s experience in Vietnam will accelerate vaccine supply to ASEAN countries through regulatory harmonization and approval process.
 
【About National Institute of Hygiene and Epidemiology (NIHE)】
NIHE is a major public health institute and the national agency for disease control and prevention under Vietnam Ministry of Health. NIHE focuses on epidemiology and medical research, serving as the national center for disease control and prevention with medical and epidemiology professionals and as a clinical trial center to conduct studies in various therapeutic areas in Vietnam.
 
【About MVC-COV1901 Vaccine】
MVC-COV1901 vaccine is constituted of genetically recombinant S-2P spike protein license from the U.S. National Institutes of Health (NIH) and CpG-1018 adjuvant collaborated with Dynavax. MVC-COV1901 vaccine has shown excellent immunogenicity data in mice and rhesus monkeys. The phase 1 clinical trial was initiated in Taiwan this September and MVC will conduct multi-regional multi-central phase 2 clinical trial in areas including Taiwan and Vietnam.
 
【About Medigen Vaccine Biologics Corp. (MVC)】
MVC is a biopharmaceutical company using cell-based technologies for the development of vaccines and biosimilars. With a goal of national self-sufficiency, MVC also aims to provide vaccines and biopharmaceuticals to meet regional needs and with a desire to help globally against the threats of infectious diseases. MVC's pipeline includes enterovirus EV71 vaccine, dengue vaccine, influenza quadrivalent vaccine which all have entered late clinical stage. MVC's large-scale production facility is state of the art and adherent to international PIC/s and GMP requirements.  For more information, visit www.medigenvac.com.